Cardiovascular Safety of Roxadustat Versus Erythropoiesis-Stimulating Agents for Treatment of Anemia in Patients With Chronic Kidney Disease Incident to or Not Receiving Dialysis: Pooled Subgroup Analysis of Four Phase 3 Studies

Ciro Esposito (1, 2) , Jonathan Barratt (3) , Frank Dellanna (4) , Jose Portoles , Gabriel Choukroun (5, 6) , Luca de Nicola , Michael Reusch , James Young , Alina Jiletcovici , Nada Dimkovic

1 IRCCS Pavia - ICS Maugeri - Istituti Clinici Scientifici Maugeri [Pavia]
2 UNIPV - Università degli Studi di Pavia = University of Pavia
3 University of Leicester
4 DaVita Clinical Research [Düsseldorf, Allemagne]
5 MP3CV - Mécanismes physiopathologiques et conséquences des calcifications vasculaires - UR UPJV 7517
6 Service de Néphrologie-Dialyse-Transplantation [CHU Amiens-Picardie]

Domaines: Médecine humaine et pathologie

Ciro Esposito, Jonathan Barratt, Frank Dellanna, Jose Portoles, Gabriel Choukroun, et al.. Cardiovascular Safety of Roxadustat Versus Erythropoiesis-Stimulating Agents for Treatment of Anemia in Patients With Chronic Kidney Disease Incident to or Not Receiving Dialysis: Pooled Subgroup Analysis of Four Phase 3 Studies. 54th Annual Meeting of the Swiss Society of Nephrology, Dec 2022, Interlaken, Switzerland. pp.23 S-24 S. ⟨hal-03960022⟩